



**Eli Lilly and Company**  
**Lilly Corporate Center**  
**Indianapolis, Indiana 46285**  
**U.S.A.**  
**(317) 276-2000**

**Patent Division**

**FACSIMILE TRANSMITTAL SHEET**

**Date: February 28, 2000**

**Total No. of Pages 3**  
**(including cover page)**

**CONFIDENTIAL**

**Please Deliver Directly To: Examiner Peter Brunovskis**  
**FAX Number: 703-308-8724**  
**From: Thomas D. Webster**  
**FAX Number: 317-276-5172**  
**Telephone Number: 317-276-3334**

**Re: Serial No. 09/280,567**  
**Our File No. X-12915**

---

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

---

Official  
PTO FAX  
2/28/00  
7 1/2  
will

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>Felicia Cazares</u> Type or print name of person signing certification	
<u>Felicia Cazares</u> Signature	<u>February 28, 2000</u> Date

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicants :	Thomas Frank Bumol, et al.	)	
Serial No. :	09/280,567	)	
Filed:	March 30, 1999	)	Group Art Unit: 1632
For:	THERAPEUTIC APPLICATIONS OF mFLINT POLYPEPTIDES	)	Examiner: P Brunovskis
Docket No. :	X-12915	)	

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 C.F.R. 1.821(f) (SEQUENCE LISTING)**

Assistant Commissioner for Patents  
Washington, D. C. 20231  
Sir:

I hereby affirm that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

  
Thomas D. Webster  
Attorney for Applicants  
Registration No. 39,872  
Phone: 317-276-3334

Eli Lilly and Company  
Patent Division/TDW  
Lilly Corporate Center

Indianapolis, Indiana 46285

February 28, 2000